Auf dieser Seite
QTTB Q32 Bio Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 5, 2026
$8,23
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$1,9152-Wochen-Tief
$23,5752-Wochen-Hoch
Marktkapitalisierung (MRQ)
$195M
P/E
3.4
EPS
$2.42
Umsatz
$54M
Ihre Abzeichen
52W-Spanne
$2–$24
Analystenbewertung
BUY
Kursziel
$40
P/E
3.4
ROE
200.3%
Nettogewinnmarge
55.5%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
QTTB Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$8.23
Marktkapitalisierung (MRQ)
$195M
P/E
3.4
EPS
$2.42
Umsatz
$54M
ROE
200.3%
52W-Spanne
$2–$24
QTTB Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 26. März 2024 | 1-for-18 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$54M2018-12-31 → 2025-12-31
EPS$2.422021-12-31 → 2025-12-31
Freier Cashflow$-34M2018-12-31 → 2025-12-31
Nettogewinnmarge55.5%2018-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | QTTB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | 3.45-Jahres-Durchschnitt ≈-57.8 | ≈-57.8 | · | · | |
| P/S | 2.05-Jahres-Durchschnitt ≈172.5 | ≈172.5 | 8.2 | Unterbewertet | |
| K/B (MRQ) | 1.85-Jahres-Durchschnitt ≈9.5 | ≈9.5 | 2.3 | Teurer | |
| Price / FCF (Kurs / FCF) | -3.25-Jahres-Durchschnitt ≈-11.7 | ≈-11.7 | · | · | |
| Price / Cash Flow (Kurs / Cashflow) | -3.25-Jahres-Durchschnitt ≈-11.9 | ≈-11.9 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 2.55-Jahres-Durchschnitt ≈10.2 | ≈10.2 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | QTTB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Operating Margin (Betriebsgewinnmarge) | 31.4%5-Jahres-Durchschnitt ≈-1468.5% | ≈-1468.5% | -312.3% | Spitzenklasse | |
| EBITDA Margin (EBITDA-Marge) | 31.4%5-Jahres-Durchschnitt ≈-1468.5% | ≈-1468.5% | -312.3% | Spitzenklasse | |
| Pretax Margin (Vorgewinnmarge) | 55.5% | · | -1.3% | Spitzenklasse | |
| Net Profit Margin (Nettogewinnmarge) | 55.5%5-Jahres-Durchschnitt ≈-127.5% | ≈-127.5% | -351.2% | Spitzenklasse | |
| ROA | 38.7%5-Jahres-Durchschnitt ≈-18.1% | ≈-18.1% | -34.5% | Spitzenklasse | |
| ROE | 200.3%5-Jahres-Durchschnitt ≈-63.1% | ≈-63.1% | -36.9% | Spitzenklasse | |
| ROIC | 40.2%5-Jahres-Durchschnitt ≈-385.1% | ≈-385.1% | 16.0% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | QTTB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 20.35-Jahres-Durchschnitt ≈7.2 | ≈7.2 | 6.8 | Starke Liquidität | |
| Quick Ratio | 4.35-Jahres-Durchschnitt ≈4.2 | ≈4.2 | 5.3 | Starke Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | QTTB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 155.9% | · | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 81.8% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | QTTB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.75-Jahres-Durchschnitt ≈0.2 | ≈0.2 | 0.3 | Spitzenklasse | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$2.4M | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
110.2%
Nächster Bericht
Nov 11, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 4, 2026 | $-0.43 | $-0.55 | 22.2% |
| 31. März 2026 | Mai 7, 2026 | $-0.54 | $-0.69 | 22.1% |
| 31. Dezember 2025 | $3.65 | $-0.88 | 515.8% | |
| 30. September 2025 | $-0.60 | $-1.21 | 50.5% | |
| 30. Juni 2025 | $-0.78 | $-1.00 | 22.0% | |
| 31. März 2025 | $-0.90 | $-1.25 | 28.3% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54M | $0 | $-7M | $3M | $34M | $3M | $2M | $5M | |
| R&D Expense | $19M | $48M | $32M | $98M | $93M | $100M | $89M | $48M | |
| SG&A Expense | $18M | $18M | $10M | $38M | $37M | $33M | $22M | $17M | |
| Operating Expenses | $37M | $66M | $42M | $136M | $130M | $133M | $112M | $65M | |
| Operating Income | $17M | $-66M | $-48M | $-133M | $-96M | $-130M | $-110M | $-60M | |
| Other Non-op | $1M | $4M | $1M | $134M | $185.0K | $2M | $6M | $4M | |
| Pretax Income | $30M | $-46M | $-53M | $1M | $-96M | · | · | · | |
| Income Tax | $0 | $21.0K | $318.0K | $715.0K | $0 | $0 | $0 | $0 | |
| Net Income | $30M | $-48M | $-54M | $-5M | $-96M | $-129M | $-104M | $-56M | |
| EPS (Basic) | $2.42 | $-5.12 | $-153.96 | $-0.09 | $-1.73 | · | · | · | |
| EPS (Diluted) | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 | · | · | · | |
| Shares (Basic) | 12,300,568 | 9,320,884 | 349,060 | 57,399,762 | 55,283,318 | · | · | · | |
| Shares (Diluted) | 12,314,796 | 9,657,696 | 349,060 | 57,399,762 | 55,283,318 | · | · | · | |
| EBITDA | $17M | $-66M | · | $-133M | $-96M | $-130M | $-110M | $-62M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48M | $78M | $26M | $34M | $108M | $217M | $54M | $38M | |
| Short-term Investments | · | $0 | $0 | $141M | · | · | · | · | |
| Prepaid Expense | $7M | $4M | $3M | $6M | $7M | $2M | $4M | $7M | |
| Other Current Assets | $20.0K | $396.0K | $83.0K | · | · | · | · | · | |
| Current Assets | $55M | $82M | $29M | $181M | $192M | $220M | $267M | $222M | |
| PP&E (Net) | $979.0K | $1M | $2M | $1M | $2M | $37M | $43M | $36M | |
| PP&E (Gross) | $3M | $3M | $3M | $7M | $8M | $53M | $51M | $38M | |
| Accum. Depreciation | $2M | $1M | $966.0K | $6M | $6M | $16M | $8M | $2M | |
| Other Non-current Assets | $0 | $116.0K | $5M | · | · | · | · | · | |
| Total Assets | $62M | $92M | $47M | $228M | $212M | $264M | $311M | $259M | |
| Accounts Payable | $879.0K | $3M | $3M | $1M | $2M | $5M | $3M | $16M | |
| Accrued Liabilities | $4M | $7M | $10M | · | · | · | · | · | |
| Current Liabilities | $11M | $16M | $14M | $23M | $17M | $23M | $12M | $23M | |
| Capital Leases | $5M | $6M | $6M | $28M | $24M | $13M | · | · | |
| Other Non-current Liabilities | $0 | $55M | $55M | · | · | · | · | · | |
| Total Liabilities | $20M | $87M | $119M | $50M | $42M | $68M | $52M | $63M | |
| Common Stock | $2.0K | $2.0K | $1.0K | $6.0K | $6.0K | $5.0K | $4.0K | $3.0K | |
| Paid-in Capital | $247M | $240M | $4M | $608M | · | · | · | · | |
| Retained Earnings | $-205M | $-235M | $-187M | $-429M | $-424M | $-328M | $-200M | $-96M | |
| AOCI | · | $0 | $0 | $-404.0K | $-7.0K | $0 | $183.0K | $-77.0K | |
| Stockholders' Equity | $42M | $6M | $-183M | $-131M | $170M | $196M | $259M | $196M | |
| Liabilities + Equity | $62M | $92M | $47M | $228M | $212M | $264M | $311M | $259M | |
| Shares Outstanding | 12,858,047 | 12,197,615 | 359,569 | 57,483,910 | 57,150,274 | 50,265,575 | 45,116,742 | 37,358,526 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $5M | $4M | $1M | $13M | $17M | $13M | $8M | $3M | |
| Deferred Tax | · | $100.0K | $300.0K | · | · | · | · | · | |
| Restructuring | · | · | $10M | · | · | · | · | · | |
| Operating Cash Flow | $-34M | $-68M | $-19M | $-114M | $-110M | $-94M | $-91M | $-43M | |
| CapEx | $0 | $75.0K | $5.0K | $1M | $2M | $4M | $22M | $25M | |
| Investing Cash Flow | $7M | $20M | $-5.0K | $37M | $-51M | $205M | $-52M | $-122M | |
| Stock Issued | $0 | $42M | $0 | $0 | $50M | · | $135M | · | |
| Net Stock Activity | $0 | $42M | · | $0 | $50M | · | $135M | · | |
| Financing Cash Flow | $-3M | $95M | $406.0K | $596.0K | $52M | $53M | $158M | $151M | |
| Net Change in Cash | · | · | $5M | $-76M | $-108M | $164M | $15M | $-13M | |
| Free Cash Flow | $-34M | $-68M | · | $-115M | $-112M | $-98M | $-113M | $-68M |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 31.4% | · | · | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1671.1% | |
| Net Margin | 55.5% | · | · | -156.0% | -281.9% | -4762.9% | -6237.4% | -1553.1% | |
| Pretax Margin | 55.5% | · | · | 37.3% | · | · | · | · | |
| EBITDA Margin | 31.4% | · | · | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1671.1% | |
| ROA | 38.7% | -68.5% | · | -2.3% | -40.3% | -44.8% | -36.5% | -28.8% | |
| ROE | 200.3% | -398.3% | · | -2.6% | -52.0% | -70.3% | -40.2% | -28.0% | |
| ROIC | 40.2% | -1165.3% | · | -30.2% | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.0 | · | 8.0 | 11.1 | 9.7 | 21.5 | 8.7 | |
| Quick Ratio | 4.3 | 4.7 | · | 1.5 | 6.3 | 9.6 | 4.3 | 1.5 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.0 | · | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.27 | $0.47 | · | $3.10 | $2.97 | $3.90 | $5.73 | $5.21 | |
| Revenue / Share | $4.36 | $0.00 | · | $0.06 | · | · | · | · | |
| Cash Flow / Share | $-2.72 | $-7.01 | · | $-1.98 | · | · | · | · | |
| Cash / Share | $3.76 | $6.39 | · | $0.59 | $1.90 | $4.33 | $1.19 | $1.02 | |
| EPS (TTM) | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 | · | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -90.6% | 1157.2% | · | · | · | |
| Revenue CAGR 3Y | 155.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 81.8% | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $54M | $0 | $-7M | $3M | $34M | $3M | $2M | $5M | |
| Net Income TTM | $30M | $-48M | $-54M | $-5M | $-96M | $-129M | $-104M | $-56M | |
| Market Cap | $43M | $42M | · | $1.30B | $3.74B | $10.21B | $16.81B | $15.04B | |
| P/E | 1.4 | -0.5 | -0.1 | -252.0 | -37.9 | · | · | · | |
| P/S | 0.8 | · | · | 406.4 | 110.2 | 3780.5 | 10090.3 | 2825.3 | |
| P/B | 1.0 | 7.4 | · | 7.3 | 22.1 | 52.1 | 65.0 | 77.2 | |
| P / Tangible Book | 1.0 | 7.4 | · | · | 22.1 | 52.1 | · | · | |
| P / Cash Flow | -1.3 | -0.6 | · | -11.5 | -34.1 | -108.3 | -184.0 | -353.3 | |
| P / FCF | -1.3 | -0.6 | · | -11.3 | -33.4 | -104.2 | -148.5 | -222.8 | |
| Earnings Yield | 72.9% | -191.3% | -1406.8% | -0.40% | -2.6% | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-15M | $2M | $3M | $3M | $802.0K | $802.0K | |
| R&D Expense | $4M | $3M | $3M | $4M | $5M | $7M | $11M | $14M | $13M | $10M | $8M | $7M | $8M | $8M | $27M | $26M | |
| SG&A Expense | $5M | $5M | $5M | $4M | $4M | $5M | $4M | $4M | $5M | $5M | $3M | $2M | $2M | $2M | $8M | $8M | |
| Operating Expenses | $9M | $8M | $8M | $8M | $9M | $12M | $15M | $19M | $18M | $15M | $11M | $10M | $10M | $10M | $35M | $34M | |
| Operating Income | $-9M | $-8M | $46M | $-8M | $-9M | $-12M | $-15M | $-19M | $-18M | $-15M | $-26M | $-8M | $-7M | $-7M | $-34M | $-33M | |
| Other Non-op | $319.0K | $113.0K | $115.0K | $188.0K | $-318.0K | $1M | $358.0K | $1M | $2M | $158.0K | $196.0K | $84.0K | $165.0K | $578.0K | $1M | $1M | |
| Pretax Income | · | · | $58M | $-7M | $-9M | $-11M | $-14M | $-18M | $-16M | $1M | $-27M | $-14M | $-6M | $-7M | $-33M | $-32M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $21.0K | $0 | $0 | $0 | $383.0K | $-65.0K | $0 | $0 | $-403.0K | $46.0K | |
| Net Income | $-9M | $-8M | $58M | $-7M | $-9M | $-11M | $-14M | $-18M | $-17M | $1M | $-27M | $-14M | $-6M | $-7M | $-34M | $-34M | |
| EPS (Basic) | $-0.44 | $-0.54 | $4.70 | $-0.60 | $-0.78 | $-0.90 | $-3.27 | $-1.46 | $-1.42 | $1.03 | $-76.91 | $-40.52 | $-16.69 | $-19.84 | $-0.60 | $-0.59 | |
| EPS (Diluted) | $-0.44 | $-0.54 | $4.70 | $-0.60 | $-0.78 | $-0.90 | $2.63 | $-1.46 | $-1.42 | $-6.33 | $-76.91 | $-40.52 | $-16.69 | $-19.84 | $-0.58 | $-0.59 | |
| Shares (Basic) | 20,342,345 | 14,095,371 | · | 12,240,542 | 12,197,615 | 12,197,615 | · | 12,076,412 | 11,964,224 | 995,280 | · | 346,288 | 347,936 | 344,623 | · | 57,447,192 | |
| Shares (Diluted) | 20,342,345 | 14,095,371 | · | 12,240,542 | 12,197,615 | 12,197,615 | · | 12,076,412 | 11,964,224 | 2,334,180 | · | 346,288 | 347,936 | 344,623 | · | 57,447,192 | |
| EBITDA | $-9M | $-8M | · | $-8M | $-9M | $-12M | · | $-19M | $-18M | $-15M | · | $-31M | $-31M | $-28M | · | $-33M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $106M | $51M | $48M | $49M | $55M | $65M | $78M | $89M | $98M | $116M | $26M | $29M | $77M | $39M | $34M | $43M | |
| Short-term Investments | · | · | · | · | · | · | · | $0 | · | · | $0 | $74M | $50M | $111M | · | · | |
| Prepaid Expense | $3M | $6M | $7M | $2M | $3M | $3M | $4M | $5M | $4M | $3M | $3M | $3M | $4M | $4M | $6M | $12M | |
| Other Current Assets | $19.0K | $20.0K | $20.0K | $24.0K | $77.0K | $93.0K | $396.0K | $229.0K | $51.0K | $67.0K | $83.0K | · | · | · | · | · | |
| Current Assets | $110M | $57M | $55M | $51M | $58M | $69M | $82M | $94M | $112M | $138M | $29M | $107M | $131M | $154M | $181M | $213M | |
| PP&E (Net) | $804.0K | $889.0K | $979.0K | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $0 | $845.0K | $1M | $1M | $1M | |
| PP&E (Gross) | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $0 | $7M | $7M | $7M | $8M | |
| Accum. Depreciation | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $966.0K | $0 | $7M | $6M | $6M | $7M | |
| Other Non-current Assets | · | · | $0 | $0 | $570.0K | $444.0K | $116.0K | $40.0K | $1M | $1M | $5M | · | · | · | · | · | |
| Total Assets | $116M | $64M | $62M | $58M | $66M | $79M | $92M | $105M | $124M | $152M | $47M | $140M | $169M | $198M | $228M | $263M | |
| Accounts Payable | $2M | $653.0K | $879.0K | $973.0K | $910.0K | $3M | $3M | $1M | $2M | $5M | $3M | $8M | $3M | $4M | $1M | $5M | |
| Accrued Liabilities | $4M | $4M | $4M | $4M | $4M | $5M | $7M | $9M | $11M | $20M | $10M | · | · | · | · | · | |
| Current Liabilities | $5M | $11M | $11M | $11M | $12M | $15M | $16M | $14M | $17M | $33M | $14M | $25M | $23M | $19M | $23M | $25M | |
| Capital Leases | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $27M | $27M | $27M | $28M | $28M | |
| Other Non-current Liabilities | · | · | $0 | $55M | $55M | $55M | $55M | $55M | $55M | $55M | $55M | · | · | · | · | · | |
| Total Liabilities | $10M | $17M | $20M | $76M | $78M | $83M | $87M | $86M | $91M | $104M | $119M | $52M | $50M | $46M | $50M | $54M | |
| Common Stock | $3.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $1.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Paid-in Capital | $327M | $259M | $247M | $244M | $243M | $242M | $240M | $239M | $237M | $235M | $4M | $614M | $612M | $610M | · | · | |
| Retained Earnings | $-222M | $-213M | $-205M | $-263M | $-255M | $-246M | $-235M | $-221M | $-203M | $-186M | $-187M | $-526M | $-493M | $-458M | $-429M | $-395M | |
| AOCI | · | · | · | $0 | $0 | $0 | · | $-1.0K | $-1.0K | $-5.0K | $0 | $-36.0K | $-88.0K | $-182.0K | $-404.0K | $-457.0K | |
| Stockholders' Equity | $106M | $46M | $42M | $-18M | $-12M | $-4M | $6M | $18M | $34M | $49M | $-183M | $88M | $119M | $152M | $178M | $209M | |
| Liabilities + Equity | $116M | $64M | $62M | $58M | $66M | $79M | $92M | $105M | $124M | $152M | $47M | $140M | $169M | $198M | $228M | $263M | |
| Shares Outstanding | 23,736,600 | 14,629,463 | 12,858,047 | 12,304,352 | 12,197,615 | 12,197,615 | 12,197,615 | 12,138,869 | 11,995,206 | 11,929,520 | 359,569 | 57,902,210 | 57,798,133 | 57,794,767 | 57,483,910 | 57,480,610 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $417.0K | $521.0K | $-4M | $-2M | $296.0K | $3M | $3M | |
| Restructuring | · | · | · | $0 | $0 | $900.0K | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-3M | $-6M | $-6M | $-4M | $-11M | $-12M | $-11M | $-20M | $-22M | $-15M | $-11M | $42M | $2M | $-12M | $-27M | $-25M | |
| CapEx | · | · | $0 | $0 | · | · | $2.0K | $58.0K | $15.0K | $0 | $0 | $-223.0K | $-224.0K | $5.0K | $9.0K | $6.0K | |
| Investing Cash Flow | $0 | $0 | $7M | $0 | $0 | $0 | $-2.0K | $10M | $10M | $97.0K | $0 | $-92M | $-31M | $-5.0K | $18M | $-108M | |
| Stock Issued | $0 | $10M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $42M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | $10M | · | · | · | $0 | · | · | · | $42M | · | · | · | · | · | · | |
| Financing Cash Flow | $59M | $9M | $-2M | $-2M | · | · | $317.0K | $997.0K | $-6M | $99M | $76.0K | $178.0K | $-120.0K | $15.0K | $32.0K | $124.0K | |
| Net Change in Cash | · | · | · | · | · | · | · | · | · | · | · | $-48M | $37M | $5M | $-9M | $-133M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-15M | · | · | · | $-26M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 3706.5% | 4021.9% | · | 3444.1% | 3229.2% | 3296.0% | · | · | · | · | · | · | -8705.1% | -3430.3% | · | -4097.5% | |
| Net Margin | 3636.6% | 3963.0% | · | 3358.6% | 3341.2% | 2973.3% | · | · | · | · | · | · | -9899.4% | -3596.5% | · | -4205.2% | |
| Pretax Margin | · | · | · | 3358.6% | 3341.2% | 2973.3% | · | · | · | · | · | · | -8278.2% | -3247.1% | · | -3939.3% | |
| EBITDA Margin | 3706.5% | 4021.9% | · | 3444.1% | 3229.2% | 3296.0% | · | · | · | · | · | · | -8705.1% | -3430.3% | · | -4097.5% | |
| ROA | -9.8% | -10.7% | · | -9.1% | -10.0% | -9.5% | · | -14.4% | -11.6% | 0.59% | · | -16.4% | -15.4% | -11.3% | · | -13.7% | |
| ROE | -19.1% | -36.0% | · | 9658.8% | -89.2% | -49.3% | · | -33.0% | -22.2% | 1.0% | · | -22.2% | -19.5% | -13.8% | · | -16.6% | |
| ROIC | · | · | · | 41.1% | 75.0% | 304.6% | · | -102.8% | -53.5% | -30.4% | · | -35.1% | -25.8% | -18.1% | · | -15.7% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 20.3 | 5.4 | · | 4.6 | 5.1 | 4.7 | · | 6.5 | 6.5 | 4.2 | · | 4.2 | 5.7 | 8.3 | · | 8.4 | |
| Quick Ratio | 19.7 | 4.8 | · | 4.4 | 4.8 | 4.5 | · | 6.2 | 5.7 | 3.5 | · | 4.1 | 5.5 | 8.1 | · | 1.7 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | -0.0 | -0.0 | · | -0.0 | -0.0 | -0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.46 | $3.17 | · | $-1.50 | $-1.00 | $-0.33 | · | $1.51 | $2.79 | $4.09 | · | $1.52 | $2.07 | $2.63 | · | $3.64 | |
| Revenue / Share | $-0.01 | $-0.01 | · | $-0.02 | $-0.02 | $-0.03 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | $0.01 | $0.01 | · | $0.01 | |
| Cash Flow / Share | · | $-0.45 | · | · | · | $-1.02 | · | · | · | $-6.23 | · | · | · | $-0.45 | · | · | |
| Cash / Share | $4.48 | $3.47 | · | $3.99 | $4.50 | $5.37 | · | $7.34 | $8.14 | $9.68 | · | $0.50 | $1.33 | $0.68 | · | $0.75 | |
| EPS (TTM) | $3.12 | $2.78 | · | $0.35 | $-0.51 | $-1.15 | · | $-86.12 | $-125.18 | $-140.45 | · | $-77.63 | $-37.70 | $-21.52 | · | $-0.14 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $-15M | $-13M | $-10M | · | $9M | $8M | $5M | · | $3M | |
| Net Income TTM | $34M | $33M | · | $-42M | $-52M | $-60M | · | $-61M | $-57M | $-46M | · | $-61M | $-81M | $-104M | · | $-4M | |
| Market Cap | $302M | $94M | · | $24M | $18M | $20M | · | $542M | $215M | $203M | · | $1.22B | $921M | $1.07B | · | $1.67B | |
| P/E | 4.1 | 2.3 | · | 5.7 | -2.9 | -1.4 | · | -0.5 | -0.1 | -0.1 | · | -0.3 | -0.4 | -0.9 | · | -207.0 | |
| P/S | · | · | · | · | · | · | · | -36.9 | -16.8 | -21.2 | · | 138.4 | 118.7 | 200.2 | · | 519.3 | |
| P/B | 2.9 | 2.0 | · | -1.3 | -1.5 | -5.0 | · | 29.6 | 6.4 | 4.2 | · | 13.8 | 7.7 | 7.1 | · | 8.0 | |
| P / Tangible Book | 2.9 | 2.0 | · | · | · | · | · | 29.6 | 6.4 | 4.2 | · | 13.8 | 7.7 | 7.1 | · | 8.0 | |
| P / Cash Flow | · | -14.8 | · | · | · | -1.6 | · | · | · | -14.0 | · | · | · | -41.1 | · | · | |
| Earnings Yield | 24.5% | 43.3% | · | 17.7% | -34.2% | -69.7% | · | -193.0% | -697.4% | -824.2% | · | -368.6% | -236.7% | -116.1% | · | -0.48% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $54M | $0 | $-7M | $3M | $34M |
| Betriebsgewinnmarge % | 31.4% | · | · | -4154.6% | -282.4% |
| Nettoergebnis | $30M | $-48M | $-54M | $-5M | $-96M |
| Verwässerte EPS | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 4.9 | 5.0 | · | 8.0 | 11.1 |
| Quick Ratio | 4.3 | 4.7 | · | 1.5 | 6.3 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-34M | $-68M | · | $-115M | $-112M |
Institutionelle Eigentümer (13F) 75 Einreicher · $283.7M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
75
Gehaltener Wert
$283.7M
Neue Positionen
29
Geschlossene Positionen
8
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 29 (+18 vs. Vorquartal) | 8 (0 vs. Vorquartal) | 17 (+3 vs. Vorquartal) | 14 (+5 vs. Vorquartal) | +13.0M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | $52.590.554 | 4.127.987 | 18,53% | Aktien |
| Boxer Capital Management, LLC | $40.122.209 | 3.149.310 | 14,14% | Aktien |
| Atlas Venture Life Science Advisors, LLC | $34.615.930 | 2.717.106 | 12,20% | Aktien |
| BVF INC/IL | $29.939.000 | 2.350.000 | 10,55% | Aktien |
| RA CAPITAL MANAGEMENT, L.P. | $29.715.502 | 2.332.457 | 10,47% | Aktien |
| Point72 Asset Management, L.P. | $14.949.065 | 1.173.396 | 5,27% | Aktien |
| Opaleye Management Inc. | $11.860.940 | 931.000 | 4,18% | Aktien |
| Logos Global Management LP | $10.192.000 | 800.000 | 3,59% | Aktien |
| SummitTX Capital, L.P. | $9.348.281 | 733.774 | 3,29% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.609.550 | 518.803 | 2,33% | Aktien |
| Ikarian Capital, LLC | $5.478.200 | 430.000 | 1,93% | Aktien |
| Woodline Partners LP | $3.646.341 | 286.212 | 1,29% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $3.474.860 | 272.752 | 1,22% | Aktien |
| Sanofi | $3.109.617 | 244.083 | 1,10% | Aktien |
| ACORN CAPITAL ADVISORS, LLC | $2.754.019 | 216.171 | 0,97% | Aktien |
| Ikarian Capital, LLC | $2.548.000 | 200.000 | 0,90% | Verkaufsoption |
| RENAISSANCE TECHNOLOGIES LLC | $2.288.104 | 179.600 | 0,81% | Aktien |
| JANE STREET GROUP, LLC | $2.073.396 | 162.747 | 0,73% | Aktien |
| MONIMUS CAPITAL MANAGEMENT, LP | $1.682.139 | 132.036 | 0,59% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $1.661.640 | 130.427 | 0,59% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $1.563.506 | 122.690 | 0,55% | Aktien |
| CITADEL ADVISORS LLC | $1.537.247 | 120.663 | 0,54% | Aktien |
| BlackRock, Inc. | $1.509.780 | 118.507 | 0,53% | Aktien |
| VANGUARD GROUP INC | $1.065.889 | 321.051 | 0,38% | Aktien |
| MARSHALL WACE, LLP | $854.153 | 67.045 | 0,30% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $843.605 | 66.217 | 0,30% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $780.962 | 61.300 | 0,28% | Verkaufsoption |
| Carlyle Group Inc. | $769.020 | 60.363 | 0,27% | Aktien |
| STATE STREET CORP | $665.206 | 52.214 | 0,23% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $631.675 | 49.582 | 0,22% | Aktien |
| Quadrature Capital Ltd | $463.685 | 36.396 | 0,16% | Aktien |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $440.970 | 34.613 | 0,16% | Aktien |
| DAFNA Capital Management LLC | $419.095 | 32.896 | 0,15% | Aktien |
| Knott David M Jr | $387.449 | 30.412 | 0,14% | Aktien |
| Affinity Asset Advisors, LLC | $353.879 | 27.777 | 0,12% | Aktien |
| Squarepoint Ops LLC | $303.085 | 23.790 | 0,11% | Aktien |
| NORTHERN TRUST CORP | $301.059 | 23.631 | 0,11% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $300.511 | 23.588 | 0,11% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $297.377 | 23.342 | 0,10% | Aktien |
| MANGROVE PARTNERS IM, LLC | $282.191 | 22.150 | 0,10% | Aktien |
| LPL Financial LLC | $231.486 | 18.170 | 0,08% | Aktien |
| UBS Group AG | $191.202 | 15.008 | 0,07% | Aktien |
| Balyasny Asset Management L.P. | $157.237 | 12.342 | 0,06% | Aktien |
| ExodusPoint Capital Management, LP | $144.421 | 11.336 | 0,05% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $139.223 | 10.928 | 0,05% | Aktien |
| XTX Topco Ltd | $138.535 | 10.874 | 0,05% | Aktien |
| MORGAN STANLEY | $82.259 | 6.456 | 0,03% | Aktien |
| Vanguard Global Advisers, LLC | $61.458 | 4.824 | 0,02% | Aktien |
| FMR LLC | $43.163 | 3.388 | 0,02% | Aktien |
| CITIGROUP INC | $36.793 | 2.888 | 0,01% | Aktien |
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VII LLC, OrbiMed Genesis GP LLC ×5 Einreichungen | 20. Juli 2026 | 13,90% | Änderung | · | SEC |
| Atlas Venture Fund X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, L.P., Atlas Venture Associates Opportunity II, LLC, Atlas Venture Opportunity Fund Ill, L.P., Atlas Venture Associates Opportunity III, L.P., Atlas Venture Associates Opportunity III, LLC ×2 Einreichungen | 28. Mai 2026 | 3,60% | Änderung | · | SEC |
| Acorn Bioventures, L.P., Acorn Capital Advisors, GP, LLC, Anders Hove | 4. April 2024 | · | Erste Einreichung | M&A / Verkauf | SEC |
| Deerfield Mgmt III, L.P., Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Deerfield Management Company, L.P., James E. Flynn ×5 Einreichungen | 1. Mai 2020 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 29 Insider · 13 Führungskräfte · 18 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Jodie Pope Morrison | CEO | 16. Juli 2026 A | 353.104 | 0 | 2 | $-122.502 |
| Albert Seymour | President and Chief Executive Officer | 6. September 2023 M | 150.874 | 0 | 0 | $0 |
| Lee Kalowski | CFO and President | 16. Juli 2026 A | 142.443 | 0 | 2 | $-49.406 |
| Paul Alloway | Former President and Chief Operating Officer of Homology Medicines, Inc. | 25. März 2024 S | 2.596 | 0 | 0 | $0 |
| Timothy P Kelly | Chief Operating Officer | 24. Februar 2022 A | 2.224 | 0 | 0 | $0 |
| Siyamak Rasty | Chief Operating Officer | 9. Juli 2019 S | 222.707 | 0 | 0 | $0 |
| Shelia M. Violette | Chief Scientific Officer | 16. Juli 2026 A | 130.569 | 0 | 1 | $-12.696 |
| Jason Campagna | Chief Medical Officer | 24. Februar 2025 A | 37.500 | 0 | 0 | $0 |
| Charles Michaud Jr | Former Vice President, Corporate Controller and Treasurer of Homology Medicines, Inc. | 25. März 2024 S | 927 | 0 | 0 | $0 |
| Julie Jordan | Chief Medical Officer | 3. August 2023 M | 7.496 | 0 | 0 | $0 |
| Michael Lee Blum | Chief Commercial Officer | 23. Februar 2023 A | 13.538 | 0 | 0 | $0 |
| Bradford W Smith | Chief Financial and Business Officer and Treasurer | 23. Februar 2023 A | 14.219 | 0 | 0 | $0 |
| Gabriel Cohn | Chief Medical Officer | 1. Januar 2022 M | 2.629 | 0 | 0 | $0 |
| Diyong Xu | Direktor | 12. Juni 2026 A | 625.000 | 2 | 0 | $15.000.000 |
| David S. Grayzel | Direktor | 12. Juni 2026 A | · | 0 | 0 | $0 |
| Sven Ante Lundberg | Direktor | 12. Juni 2026 A | · | 0 | 0 | $0 |
| Isaac Manke | Direktor | 12. Juni 2026 A | 53.521 | 0 | 0 | $0 |
| Arthur Tzianabos | Direktor | 12. Juni 2026 A | 7.983 | 0 | 0 | $0 |
| Mark T Iwicki | Direktor | 12. Juni 2026 A | · | 0 | 0 | $0 |
| Mary Thistle | Direktor | 12. Juni 2026 A | · | 0 | 0 | $0 |
| Kathleen Laporte | Direktor | 12. Juni 2026 A | · | 0 | 0 | $0 |
| Jeffrey V. Poulton | Direktor | 14. Juni 2023 A | · | 0 | 0 | $0 |
| Alise Reicin | Direktor | 14. Juni 2023 A | · | 0 | 0 | $0 |
| Matthew R Patterson | Direktor | 14. Juni 2023 A | · | 0 | 0 | $0 |
| Steven Gillis | Direktor | 14. Juni 2023 A | 6.068.695 | 0 | 0 | $0 |
| Kush Parmar | Direktor | 15. Juni 2022 A | 181.435 | 0 | 0 | $0 |
| Richard J. Gregory | Direktor | 15. Juni 2022 A | 10.806 | 0 | 0 | $0 |
| Cameron Wheeler | Direktor | 6. Juni 2019 A | · | 0 | 0 | $0 |
| Mahendra Shah | Direktor | 2. April 2018 A | 909.742 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 5 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,29% | 8.018 SH | 1. Oktober 2026 | Täglich |
| IWC · iShares Trust | 0,02% | 29.271 SH | 11. September 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,00% | 14.652 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 119.269 SH | 19. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 389.115 SH | 19. August 2026 | Täglich |
QTTB Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 12 Analysten
KAUF
Median-Ziel
$36.00
+337,4%
3 25,0%
Starker Kauf
8 66,7%
Kauf
1 8,3%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
5 Analysten · 2026-09-29Mittelwert-Ziel $39.60 +381,2%
← Unter allen Zielen
Aktueller Preis $8.23
Tief$29.00
Mittelwert$39.60
Hoch$59.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| QTTB | $43M | 1.4 | · | 55.5% | 200.3% | · |
| PALI | $375M | -7.8 | · | · | -25.4% | · |
| STRO | $99M | -0.5 | 65.2% | -186.5% | 232.2% | · |
| CAMP | $318M | -2.3 | 436.5% | -2298.5% | -183.4% | · |
| EVMN | $540M | -1.5 | 85.7% | -529.8% | -401.2% | · |
| GLSI | $300M | -14.7 | · | · | -2159.7% | · |
| IVVD | $697M | -8.2 | 110.5% | -98.2% | -36.9% | · |
| AKBA | $427M | -80.5 | 47.5% | -2.3% | -17.3% | · |
| MGNX | $102M | -1.4 | -0.31% | -49.9% | -87.0% | · |
| LYEL | $654M | -1.9 | -41.0% | -762355.6% | -100.3% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 5, 2026